A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Phase of Trial: Phase III
Latest Information Update: 17 Jul 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DICIPLE
- 31 Aug 2018 Biomarkers information updated
- 09 Jul 2018 Planned End Date changed from 1 Apr 2023 to 1 May 2023.
- 09 Jul 2018 Planned primary completion date changed from 1 Apr 2023 to 1 May 2023.